European Industry Urges Action On Unequal Access To Biosimilars
Cites ‘Inequity Across EU Member States’ As A ‘Major Concern’ To Address At All Levels
Executive Summary
As the European Commission held an annual event for biosimilars industry stakeholders, Medicines for Europe highlighted continuing inequalities in access across Europe and called for both EU- and national-level action to address this “major concern.”